## **NHS BORDERS - AREA DRUG & THERAPEUTIC COMMITTEE**



## NOTES/MINUTE FROM VIRTUAL DECISIONS IN PLACE OF MEETING - WEDNESDAY 13<sup>TH</sup> MAY 2020

**SENT TO:** Alison Wilson (Director of Pharmacy) (Chair) (AW); Keith Maclure (Lead Pharmacist – Medicines Utilization & Planning) (KMacl); Adrian Mackenzie (Lead Pharmacist Community) (AMack); Dr Nicola Henderson (GP) (NH); Liz Leitch (Formulary Pharmacist) (LL); Keith Allan (Public Health Consultant); Dr Edward James (Consultant Microbiologist) (EJ); Cathryn Park (Lead Pharmacist – Acute Care & Medicines Governance) (CP); Mark Clark (Non Medical Prescribing Lead/Infection Control Lead) (MC); Andrew Leitch (Lay Member) (AL); Dr Gemma Alcorn (Locum Consultant Physician DME); Kate Warner (Minute Secretary) (KW)

ITEM	SITUATION ; BACKGROUND ; ASSESSMENT	RECOMMENDATION	COMMENTS			
1	APOLOGIES AND ANNOUNCEMENTS					
	None					
2	DECLARATIONS OF INTEREST					
	Please note any declarations of interest in Comments					
3	DRAFT MINUTE – Previous Meeting					
3.1	ADTC meeting 11 <sup>th</sup> March 2020 Approval was received from AW; KMacl; AMack; GA; NH	Approved	No changes to be made; save and upload to Intranet/Internet (KW)			
4	Matters Arising					
	None					
5	NEW MEDICINE APPLICATIONS					
	None					
6	PATIENT & MEDICINE SAFETY					
	None					
7	CLINICAL POLICIES, PROCEDURES AND GUIDELINES – FOR APPROVAL					
7.1	Medicines Governance during Covid19 - Adapted from Lothian paper Approval was received from AW; KMacl; AMack; GA; NH	Approved				
7.2	Disease Modifying Anti-Rheumatic Drugs (DMARDs); Reviewed by D Evans; Dr A Mackenzie; Dr D Simpson; F Bathgate Approval was received from AW; KMacl; AMack; GA; NH Comment from KMacl	r C Approved	KMacl was interested to hear GP opinion. Seems to be a wide variation in risk from monitoring			

7.3	Equality & Diversity Report for Homecare Policy was required Governance for the Homecare Policy Approval was received from AW; KMacl; AMack; GA; NH Comment from AW	d by Clinical	Approved	AW commented that this looked very comprehensive.		
7.5	General Dental Practice remote prescribing process – to streamline the process to reduce stress for patients, practitioners and pharmacists. Approval was received from AW; KMacl; AMack; GA; NH Comment from KMacl		Approved	KMacl commented that box 2, 2 <sup>nd</sup> line should be a phone call to alert the Pharmacy of imminent electronic transfer of a prescription. Telephoning the content of the prescription is an unnecessary exercise and could be misinterpreted.		
8	FOR INFORMATION AND NOTING					
8.1	Spreadsheet outlining changes made to documents and procedures duri Covid19 Tabs for each procedure or policy change.		Noted			
8.2	NHS Borders Anticoagulation Advice for appropriate and safe conversion of patients from Warfarin to a DOAC during the Covid19 pandemic	8.2 – 8.5 items have been	Noted			
8.3	Anticoagulation Bridging for Patients with severe renal impairment or end stage renal disease	updated recently in	Noted			
8.4	Information for clinicians managing Covid19 patients in NHS Borders – thromboprophylaxis, VTE in patients with Covid19 and DIC and blood product support	response to Covid19 and details of	Noted			
8.5	Guidance and Pathway for End of Life Care patients	e Care patients change 8.1				
8.6	Guidance for intravenous fluid and electrolyte prescription in adults has been updated to reflect changes to Potassium Chloride IV Monograph.					
9	FEEDBACK & MINUTES – SUB-GROUPS					
9.1	Borders Formulary Committee					
9.2	Antimicrobial Management Team					
9.3	Anticoagulant Committee					
9.4	IV Therapy Group > No further meeting	g minutes availat	ious ADTC			
9.5	Tissue Viability Group					
9.6	Wound Formulary Group					
9.7	NHS Lothian ADTC					

10	AOCB		
	None		
DATE AND TIME OF NEXT MEETING : 8 <sup>th</sup> July 2020; 12:30			